Clinical trialNCT06439602CompletedPhase 3Interventional

Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

SponsorArthrosi TherapeuticsEnrollment818Arthritis, GoutyGoutGout ChronicHyperuricemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Robert Keenan, MD
Arthrosi Therapeutics, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

68 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Australia

Arthrosi Investigative Site (202)
Botany, New South Wales, Australia
Arthrosi Investigative Site (200)
Camberwell, Victoria, Australia

Hong Kong

Arthrosi Investigative Site (500)
Hong Kong, Central, Hong Kong
Arthrosi Investigative Site (501)
Hong Kong, Hong Kong Island, Hong Kong

New Zealand

Arthrosi Investigative Site (300)
Auckland, Auckland, New Zealand
Arthrosi Investigative Site (304)
Hamilton, Hamilton, New Zealand
Arthrosi Investigative Site (302)
Auckland, New Zealand, New Zealand
Arthrosi Investigative Site (303)
Nelson, New Zealand, New Zealand
Arthrosi Investigative Site (301)
Rotorua, New Zealand, New Zealand

Taiwan

Arthrosi Investigative Site (405)
Hualien City, Taiwan, Taiwan
Arthrosi Investigative Site (404)
Kaohsiung City, Taiwan, Taiwan
Arthrosi Investigative Site (400)
Taipei, Taiwan, Taiwan
Arthrosi Investigative Site (403)
Taipei, Taiwan, Taiwan
Arthrosi Investigative Site (401)
Taoyuan City, Taiwan, Taiwan
Arthrosi Investigative Site (406)
Kaohsiung City, Taiwan
Arthrosi Investigative Site (402)
Taichung, Taiwan

United States

Arthrosi Investigative Site (106)
Foley, Alabama, United States
Arthrosi Investigative Site (139)
Anchorage, Alaska, United States
Arthrosi Investigative Site (160)
Peoria, Arizona, United States
Arthrosi Investigative Site (112)
Phoenix, Arizona, United States
Arthrosi Investigative Site (114)
Tempe, Arizona, United States
Arthrosi Investigative Site (131)
El Cajon, California, United States
Arthrosi Investigative Site (117)
Encinitas, California, United States
Arthrosi Investigative Site (138)
Rancho Cucamonga, California, United States
Arthrosi Investigative Site (161)
Valencia, California, United States
Arthrosi Investigative Site (101)
Aurora, Colorado, United States
Arthrosi Investigative Site (149)
Clearwater, Florida, United States
Arthrosi Investigative Site (115)
Coral Gables, Florida, United States
Arthrosi Investigative Site (128)
DeLand, Florida, United States
Arthrosi Investigative Site (102)
Hollywood, Florida, United States
Arthrosi Investigative Site (156)
Maitland, Florida, United States
Arthrosi Investigative Site (103)
Miami, Florida, United States
Arthrosi Investigative Site (157)
Palmetto Bay, Florida, United States
Arthrosi Investigative Site (151)
Winter Haven, Florida, United States
Arthrosi Investigative Site (164)
Atlanta, Georgia, United States
Arthrosi Investigative Site (162)
Lilburn, Georgia, United States
Arthrosi Investigative Site (133)
Boise, Idaho, United States
Arthrosi Investigative Site (122)
River Forest, Illinois, United States
Arthrosi Investigative Site (154)
Wichita, Kansas, United States
Arthrosi Investigative Site (144)
New Orleans, Louisiana, United States

28 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AR882 50 mgAR882 75 mgPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 26 Jun 2024
Primary completion: 20 Mar 2026
Completion: 10 Apr 2026
Last update posted: 14 Oct 2026
Registered enrollment: 818
Registry id: NCT06439602

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.